

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis

Claire Harrison,¹ Abdulraheem Yacoub,² Bart Scott,³ Adam Mead,⁴ Aaron T. Gerds,⁵ Jean-Jacques Kiladjian,⁶ Ruben Mesa,⁷ Miklos Egyed,⁸ Christof Scheid,⁹ Valentin Garcia Gutierrez,¹⁰ Jennifer O'Sullivan,⁴ Sarah Buckley,¹¹ Kris Kanellopoulos¹¹ and John Mascarenhas¹²

¹Guy's and St Thomas' NHS Foundation Trust, London, UK; ²The University of Kansas Cancer Center, Kansas City, KS, USA; ³Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁴University of Oxford, Oxford, UK; ⁵Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; ⁶Hôpital Saint-Louis, Université Paris Cité, Paris, France; ⁷Mays Cancer Center at UT Health San Antonio, San Antonio, TX, USA; ⁸Somogy County Mór Kaposi General Hospital, Kaposvár, Hungary; ⁹Universitätsklinikum Köln (AöR), Cologne, Germany; ¹⁰Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; ¹¹CTI BioPharma Corp, Seattle, WA, USA and ¹²Icahn School of Medicine at Mount Sinai, New York, NY, USA

Correspondence: C. HARRISON - Claire.Harrison@gstt.nhs.uk

<https://doi.org/10.3324/haematol.2022.282089>

SUPPLEMENTAL DATA**Supplemental Table 1. SAEs Reported as Possibly Treatment-Related in Patients Receiving Compassionate Use Pacritinib**

	Patients with SAE (N=76)				
	Grade 2	Grade 3	Grade 4	Grade 5	Any Grade
Any SAE	6	26	4	9	35
Possibly related SAE	3	10	1	2	16
Treatment-Related SAEs (Preferred Term)					
Subdural hematoma	0	2	1	0	3
Colitis	0	2	0	0	2
Electrocardiogram QT prolonged	2	0	0	0	2
Pneumonia	0	1	0	1	2
Abscess jaw	0	1	0	0	1
Anemia	0	1	0	0	1
Atrial enlargement	0	1	0	0	1
Cardiac failure	0	0	0	1	1
Epistaxis	0	1	0	0	1
Lung infiltration	1	0	0	0	1
Respiratory failure	0	1	0	0	1
Retroperitoneal hemorrhage	0	0	0	1	1
Tremor	0	1	0	0	1